Search for: "United States v. Lowe's Inc" Results 681 - 700 of 1,149
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
6 Mar 2013, 9:43 am by Jim Walker
Asignacion, Complainant, vs Rickmers Marine Agency Philippine, Inc. [read post]
25 Jan 2013, 1:20 pm by WIMS
      The Act requires that more than three quarters of advanced biofuel sold in the United States after January 1, 2022 be cellulosic biofuel. [read post]
18 Jan 2013, 2:06 pm by Bexis
  The Decherts are too involved in this litigation to comment publicly.There aren’t many research-oriented pharmaceutical companies based in Alabama, and after last week’s execrable decision in Wyeth, Inc. v. [read post]
16 Jan 2013, 10:14 pm by Florian Mueller
Apple's petition mentions that two months after the Galaxy Nexus decision, another Federal Circuit panel issued a more injunction-friendly ruling in a different IT patent case (Presidio Components, Inc. v. [read post]
10 Jan 2013, 4:00 am by Ian Mackenzie
… Courts are reluctant to second-guess a tribunal's decision not to hold an oral hearing and will generally only intervene to prevent manifest unfairness: Xwave Solutions Inc v. [read post]
3 Jan 2013, 5:00 am by Kimberly A. Kralowec
United Parcel Serv., Inc., 511 F.3d 974, 985 (9th Cir. 2007) (en banc) (“In a class action, standing is satisfied if at least one named plaintiff meets the requirements. [read post]
2 Jan 2013, 9:17 am by Lawrence B. Ebert
Robie, 187 F.2d 150, 152 (C.C.P.A. 1951)) AND to Catalina Marketing International, Inc. v. [read post]
27 Dec 2012, 3:47 pm by Bexis
Instead a duty-to-withdraw claim strikes at the heart of the FDA’s power to determine what prescription drugs are properly sold in interstate commerce in the United States:[A] state law duty that would compel generic manufacturers to stop production of a drug that under federal law they have the authority to produce . . . would directly conflict with the federal statutory scheme in which Congress vested sole authority with the FDA to determine whether a drug may be… [read post]
24 Nov 2012, 12:38 pm by Schachtman
In addition, Havner requires that a plaintiff show ‘that he or she is similar to [the subjects] in the studies’ and that ‘other plausible causes of the injury or condition that could be negated [are excluded] with reasonable certainty’.40” 347 S.W.3d at 265 (quoting from Merrell Dow Pharmaceuticals, Inc. v. [read post]
16 Nov 2012, 9:14 am
In the most recent decision, the Arbitration Panel specifically found that: Claimants are recent immigrants to the United States and they had very limited investment experience. [read post]